nach oben

Erschienen in:

01.05.2019 | Gynecologic Oncology

Muscle mass loss in patients with metastatic breast cancer

verfasst von: Erich-Franz Solomayer, Eva-Marie Braun, Julia Sarah Maria Zimmermann, Julia Caroline Radosa, Jonas Stroeder, Jan Endrikat, Christoph Gerlinger

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess the change of body mass index (BMI), muscle mass, visceral and subcutaneous fat in patients with metastatic breast cancer.

Methods

In this retrospective chart analysis, patients with metastatic breast cancer as initial diagnosis between 2012 and 2016 were analyzed. Patients had received either chemotherapy (CTH) or endocrine therapy (ETH) according to the German S3 Guideline. BMI was calculated from the patients’ weight and height. Change of muscle mass, visceral and subcutaneous fat was determined by comparing the surface area of these tissues on transverse CT images at the level of the third lumbar vertebrae (L3) at baseline and during treatment.

Results

A total of 45 patients were included in the study, 29 on CTH and 16 on ETH. BMI, visceral and subcutaneous fat remained stable over time for both treatment groups. When taking both treatment groups together, muscle mass decreased significantly by 5.0 ± 2.5 cm² per year (p < 0.05).

Conclusion

In patients with metastatic breast cancer, a slight reduction of muscle mass was observed, independent of therapy regimes.

GLOBOCAN 2012 (IARC), section of cancer surveillance (5/6/2018). http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 6 Dec 2018

Deutsches Krebsregister Robert Koch Institut 05/2018. https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2017/kid_2017_c50_brust.pdf. Accessed 6 Dec 2018

Neuhouser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty CL et al (2015) Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the women’s health initiative randomized clinical trials. JAMA Oncol 1:611–621CrossRefPubMedPubMedCentral

Haykowsky MJ, Scott JM, Hudson K, Denduluri N (2017) Lifestyle interventions to improve cardiorespiratory fitness and reduce breast cancer recurrence. Am Soc Clin Oncol Educ Book 37:57–64CrossRefPubMed

Ligibel JA, Strickler HD (2013) Obesity and its impact on breast cancer: tumor incidence, recurrence, survival, and possible interventions. Am Soc Clin Oncol Educ Book 2013:52–59. https://doi.org/10.1200/EdBook_AM.2013.33.52 CrossRef

Arce-Salinas C, Aguilar-Ponce JL, Villarreal-Garza C, Lara-Medina FU, Olvera-Caraza D, Alvarado Miranda A et al (2014) Overweight and obesity as poor prognostic factors in locally advanced breast cancer patients. Breast Cancer Res Treat 146:183–188CrossRefPubMed

Chan DS, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A et al (2014) Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25:1901–1914CrossRefPubMedPubMedCentral

Demark-Wahnefried W, Peterson BL, Winer EP, Marks L, Aziz N, Marcom PK et al (2001) Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 19:2381–2389CrossRefPubMed

Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L et al (2002) Obesity, body size, and risk of postmenopausal breast cancer: the Women’s Health Initiative (United States). Cancer Causes Control 13:741–751CrossRefPubMed

10.

Caan BJ, Cespedes Feliciano EM, Prado CM, Alexeeff S, Kroenke CH, Bradshaw P et al (2018) Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer. JAMA Oncol 4:798–804CrossRefPubMedPubMedCentral

11.

Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC (2009) Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 15:6973–6979CrossRefPubMed

12.

Rutten IJ, van Dijk DP, Kruitwagen RF, Beets-Tan RG, Olde Damink SW, van Gorp T (2016) Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients. J Cachexia Sarcopenia Muscle 7:458–466CrossRefPubMedPubMedCentral

13.

Leitlinie Mammacarcinom Version 4.0, 2017. http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom. Accessed 6 June 2018

14.

Rier HN, Jager A, Sleijfer S, van Rosmalen J, Kock M, Levin MD (2017) Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy. Breast 31:9–15CrossRefPubMed

15.

Feliciano EC, Chen WY (2018) Clinical implications of low skeletal muscle mass in early-stage breast and colorectal cancer. Proc Nutr Soc 77:1–6CrossRef

16.

Weinberg MS, Shachar SS, Muss HB, Deal AM, Popuri K, Yu H et al (2017) Beyond sarcopenia: characterization and integration of skeletal muscle quantity and radiodensity in a curable breast cancer population. Breast J 24:278–284CrossRefPubMedPubMedCentral

17.

Deluche E, Leobon S, Desport JC, Venat-Bouvet L, Usseglio J, Tubiana-Mathieu N (2018) Impact of body composition on outcome in patients with early breast cancer. Support Care Cancer 26:861–868CrossRefPubMed

18.

Villaseñor A, Ballard-Barbash R, Baumgartner K, Baumgartner R, Bernstein L, McTiernan A, Neuhouser ML (2012) Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study. J Cancer Surviv 6(4):398–406. https://doi.org/10.1007/s11764-012-0234-x CrossRefPubMedPubMedCentral

19.

Shachar SS, Deal AM, Weinberg M, Nyrop KA, Williams GR, Nishijima TF et al (2017) Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy. Clin Cancer Res 23:658–665CrossRefPubMed

20.

Rolland Y, Czerwinski S, Abellan Van Kan G, Morley JE, Cesari M, Onder G et al (2008) Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging 12:433–450CrossRefPubMedPubMedCentral

21.

Husebo AM, Dyrstad SM, Mjaaland I, Soreide JA, Bru E (2014) Effects of scheduled exercise on cancer-related fatigue in women with early breast cancer. Sci World J 2014:271828

22.

Travier N, Velthuis MJ, Steins Bisschop CN, van den Buijs B, Monninkhof EM, Backx F et al (2015) Effects of an 18-week exercise programme started early during breast cancer treatment: a randomised controlled trial. BMC Med 13:121CrossRefPubMedPubMedCentral

23.

Jackson RD, Mysiw WJ (2014) Insights into the epidemiology of postmenopausal osteoporosis: the Women’s Health Initiative. Semin Reprod Med 32:454–462CrossRefPubMed

24.

Scott JM, Iyengar NM, Nilsen TS, Michalski M, Thomas SM, Herndon J 2nd et al (2018) Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: a randomized controlled trial. Cancer 124:2552–2560CrossRefPubMed

25.

Yee J, Davis GM, Beith JM, Wilcken N, Currow D, Emery J et al (2014) Physical activity and fitness in women with metastatic breast cancer. J Cancer Surviv 8:647–656CrossRefPubMed

26.

Courneya KS, Segal RJ, McKenzie DC, Dong H, Gelmon K, Friedenreich CM et al (2014) Effects of exercise during adjuvant chemotherapy on breast cancer outcomes. Med Sci Sports Exerc 46:1744–1751CrossRefPubMed

27.

Versteeg KS, Blauwhoff-Buskermolen S, Buffart LM, de van der Schueren MAE, Langius JAE, Verheul HMW et al (2018) Higher muscle strength is associated with prolonged survival in older patients with advanced cancer. Oncologist 23:580–585CrossRefPubMed

28.

Hida T, Harada A (2013) Fall risk and fracture. Diagnosing sarcopenia and sarcopenic leg to prevent fall and fracture: its difficulty and pit falls. Clin Calcium 23:707–712PubMed

29.

Kim TH, Chang JS, Kong ID (2017) Effects of exercise training on physical fitness and biomarker levels in breast cancer survivors. J Lifestyle Med 7:55–62CrossRefPubMedPubMedCentral

Titel: Muscle mass loss in patients with metastatic breast cancer
verfasst von: Erich-Franz Solomayer
Eva-Marie Braun
Julia Sarah Maria Zimmermann
Julia Caroline Radosa
Jonas Stroeder
Jan Endrikat
Christoph Gerlinger
Publikationsdatum: 01.05.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 1/2019
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-019-05168-y

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Muscle mass loss in patients with metastatic breast cancer